Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer
| Autor: | Rachel M. Richards, Elizabeth A. Keating, Jean Boucher |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class medicine.medical_treatment Estrogen receptor Breast Neoplasms Targeted therapy 03 medical and health sciences 0302 clinical medicine Breast cancer Estrogen Receptor Modulators Internal medicine medicine Humans Neoplasm Metastasis Aromatase General Environmental Science 030504 nursing biology Aromatase Inhibitors business.industry Treatment options medicine.disease Metastatic breast cancer Estrogen 030220 oncology & carcinogenesis biology.protein General Earth and Planetary Sciences Female 0305 other medical science business |
| Zdroj: | Clinical Journal of Oncology Nursing. 23:434-438 |
| ISSN: | 1538-067X 1092-1095 |
| DOI: | 10.1188/19.cjon.434-438 |
| Popis: | Standard therapies for treating hormone-sensitive metastatic breast cancer (BC) include the blockage of estrogen pathways by using selective estrogen modulator receptors or selective estrogen receptor downregulators and by using aromatase inhibitors to block estrogen production. The addition of nonhormonal targeted therapies, including therapies based on alternative molecular pathways, continues to expand rapidly for advanced or metastatic BC. This article reviews targeted therapy treatment options for patients with metastatic BC, including strategies for administration, side effects, and nursing considerations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|